Devereux C, Troiano R, Zito G, Devereux R B, Kopecky K J, Friedman R, Dowling P C, Hafstein M P, Rohowsky-Kochan C, Cook S D
Department of Radiation Oncology, Clara Maass Medical Center, Belleville, NJ.
Neurology. 1988 Jul;38(7 Suppl 2):32-7.
To determine whether immunosuppression by total lymphoid irradiation (TLI) slowed deterioration of chronic progressive multiple sclerosis (MS), functional impairment score and blood lymphocyte counts were compared at 6-month intervals through 4 years following treatment of MS patients by either TLI (n = 27) or sham irradiation (n = 21). At each interval, 20 to 30% fewer TLI-treated patients had deteriorated (p less than 0.05 at 6, 12, and 18 months), and the difference in mean functional impairment score between groups became progressively greater (p less than 0.01 at 42 and 48 months). Benefit accrued principally to the 17 TLI-treated patients with absolute blood lymphocyte counts less than 900/mm3 3 months after treatment, whose mean functional impairment score remained within 0.6 units of baseline (p = NS), whereas the ten TLI patients with higher post-treatment lymphocyte counts had progressive deterioration (p less than 0.05 to p less than 0.001 versus TLI-treated patients with lower lymphocyte counts at all intervals except 30 months) and had deteriorated by more than 5 functional scale units by 42 and 48 months. Side effects were minor and complications rare in TLI-treated patients, but one TLI-treated patient developed staphylococcal sepsis. Thus, TLI slows deterioration of chronic progressive MS, with what appears to be enduring benefit through 4 years compartmented to patients with greater induced lymphopenia. Modification of lymphoid irradiation regimens to increase the proportion of MS patients who achieve a favorable degree of lymphopenia and to avert functional hyposplenism may further improve the benefit/risk ratio.
为了确定全身淋巴照射(TLI)导致的免疫抑制是否会减缓慢性进行性多发性硬化症(MS)的病情恶化,对接受TLI治疗的MS患者(n = 27)或假照射(n = 21)治疗后4年期间每6个月的功能损害评分和血液淋巴细胞计数进行了比较。在每个时间间隔,接受TLI治疗的病情恶化患者减少了20%至30%(在6、12和18个月时p < 0.05),两组之间的平均功能损害评分差异逐渐增大(在42和48个月时p < 0.01)。获益主要出现在治疗3个月后绝对血液淋巴细胞计数低于900/mm³的17例接受TLI治疗的患者中,其平均功能损害评分保持在基线的0.6单位以内(p = 无显著性差异),而另外10例治疗后淋巴细胞计数较高的TLI患者病情呈进行性恶化(除30个月外,在所有时间间隔与淋巴细胞计数较低的TLI治疗患者相比,p < 0.05至p < 0.001),到42和48个月时功能量表评分恶化超过5个单位。TLI治疗的患者副作用较小,并发症罕见,但有1例接受TLI治疗的患者发生了葡萄球菌败血症。因此,TLI减缓了慢性进行性MS的病情恶化,对于诱导淋巴细胞减少程度较高的患者,似乎在4年内都有持久的益处。调整淋巴照射方案,以增加达到有利淋巴细胞减少程度的MS患者比例,并避免功能性脾功能减退,可能会进一步改善获益/风险比。